|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.34 | 89.43 | 104.26 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
265.00
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
(Rs. in Million) | Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Audited / UnAudited | UnAudited | UnAudited | UnAudited | Audited | Net Sales | 1,721.01 | 1,495.32 | 1,614.81 | 1,573.10 | Total Expenditure | 1,481.09 | 1,315.72 | 1,475.05 | 1,430.77 | PBIDT (Excl OI) | 239.92 | 179.60 | 139.76 | 142.33 | Other Income | 36.57 | 21.49 | 34.70 | 10.37 | Operating Profit | 276.49 | 201.09 | 174.45 | 152.70 | Interest | 1.42 | 0.88 | 0.22 | 0.23 | Exceptional Items | 0 | 0 | 0 | 0 | PBDT | 275.07 | 200.21 | 174.23 | 152.47 | Depreciation | 22.02 | 21.46 | 20.09 | 24.07 | Profit Before Tax | 253.05 | 178.75 | 154.14 | 128.40 | Tax | 61.93 | 40.40 | 36.61 | 32.17 | Provisions and contingencies | 0 | 0 | 0 | 0 | Profit After Tax | 191.12 | 138.35 | 117.53 | 96.23 | Extraordinary Items | 0 | 0 | 0 | 0 | Prior Period Expenses | 0 | 0 | 0 | 0 | Other Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | Net Profit | 191.12 | 138.35 | 117.53 | 96.23 | Equity Capital | 250.56 | 250.56 | 250.56 | 250.56 | Face Value (IN RS) | 5 | 5 | 5 | 5 | Reserves | | | | | Calculated EPS | 3.81 | 2.76 | 2.35 | 1.92 | Calculated EPS (Annualised) | 15.26 | 11.04 | 9.38 | 7.68 | No of Public Share Holdings | 15,064,960.00 | 14,735,654.00 | 14,735,404.00 | 14,736,404.00 | % of Public Share Holdings | 30.06 | 29.41 | 29.41 | 29.41 | | | | | | PBIDTM% (Excl OI) | 13.94 | 12.01 | 8.65 | 9.05 | PBIDTM% | 16.07 | 13.45 | 10.80 | 9.71 | PBDTM% | 15.98 | 13.39 | 10.79 | 9.69 | PBTM% | 14.70 | 11.95 | 9.55 | 8.16 | PATM% | 11.11 | 9.25 | 7.28 | 6.12 | | Notes | Notes | Notes | Notes |
|
|
|
|
|
|